Potential Vaccines and Post-Exposure Treatments for Filovirus Infections

Viruses

Brian M. Friedrich¹  John C. Trefry¹  Julia E. Biggins¹  Lisa E. Hensley²  Anna N. Honko¹  Darci R. Smith¹ 

[1]United States Army Medical Research Institute of Infectious Diseases, Division of Virology, 1425 Porter Street, Frederick, MD 21702, USA

[2]United States Food and Drug Administration (FDA), Medical Science Countermeasures Initiative (McMi), 10903 New Hampshire Avenue, Silver Spring, MD 20901, USA

关键词: filovirus;    Ebola;    ebolavirus;    Marburg virus;    marburgvirus;    vaccines;    post-exposure treatments;    clinical trials;    non-human primates;    animal models;   

DOI  :  10.3390/v4091619

来源: mdpi

【 摘 要 】

Viruses of the family Filoviridae represent significant health risks as emerging infectious diseases as well as potentially engineered biothreats. While many research efforts have been published offering possibilities toward the mitigation of filoviral infection, there remain no sanctioned therapeutic or vaccine strategies. Current progress in the development of filovirus therapeutics and vaccines is outlined herein with respect to their current level of testing, evaluation, and proximity toward human implementation, specifically with regard to human clinical trials, nonhuman primate studies, small animal studies, and in vitro development. Contemporary methods of supportive care and previous treatment approaches for human patients are also discussed.

【 授权许可】

CC BY   
© 2012 by the authors; licensee MDPI, Basel, Switzerland.